股息配發率   玩股撇步(動畫小學堂)

  • 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: 166.66%
  • 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
  • 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
EPS YoY現金股利 YoY股票股利 YoY現金配發率 YoY股票配發率 YoY全部配發率 YoY
2024 (10)-0.7500.0000.0000.0000.0000.000
2023 (9)-1.8100.50400.00.0000.0000.0000.000
2022 (8)0.03-97.170.1000.000333.3300.000333.330
2021 (7)1.0600.0000.0000.0000.0000.000
2020 (6)-0.9200.0000.0000.0000.0000.000
2019 (5)-0.6100.0000.0000.0000.0000.000
2018 (4)-0.8800.0000.0000.0000.0000.000
2017 (3)-0.3900.0000.0000.0000.0000.000
每股盈餘-近20季
EPS QoQ YoY本業EPS QoQ YoY累計EPS QoQ YoY
24Q4 (20)-0.66-1220.073.49-0.48-585.71-150.53-0.75-733.3358.56
24Q3 (19)-0.05-155.56-200.0-0.070.022.22-0.09-125.0-113.24
24Q2 (18)0.09169.23-89.29-0.0769.5772.0-0.0469.23-106.35
24Q1 (17)-0.1394.7838.1-0.23-124.21-109.09-0.1392.8238.1
23Q4 (16)-2.49-5080.0-536.840.951155.56480.0-1.81-366.18-6133.33
23Q3 (15)0.05-94.05-16.67-0.0964.035.710.687.94223.64
23Q2 (14)0.84500.0380.0-0.25-127.27-38.890.63400.0198.44
23Q1 (13)-0.21-136.8436.36-0.1156.0-22.22-0.21-800.036.36
22Q4 (12)0.57850.035.71-0.25-78.57-56.250.03105.45-97.17
22Q3 (11)0.06120.0-83.33-0.1422.22-600.0-0.5514.06-182.09
22Q2 (10)-0.309.09-168.18-0.18-100.0-212.5-0.64-93.94-306.45
22Q1 (9)-0.33-178.57-153.85-0.0943.75-550.0-0.33-131.13-153.85
21Q4 (8)0.4216.67231.25-0.16-700.0-220.01.0658.21215.22
21Q3 (7)0.36-18.18238.46-0.02-112.581.820.67116.13211.67
21Q2 (6)0.44438.46276.00.16700.0180.00.31338.46191.18
21Q1 (5)-0.1359.38-44.440.02140.0140.0-0.1385.87-44.44
20Q4 (4)-0.32-23.080.0-0.0554.550.0-0.92-53.330.0
20Q3 (3)-0.26-4.00.0-0.1145.00.0-0.60-76.470.0
20Q2 (2)-0.25-177.780.0-0.20-300.00.0-0.34-277.780.0
20Q1 (1)-0.090.00.0-0.050.00.0-0.090.00.0
年/月營收月增率(%)去年同期年增率(%)累計營收累計營收年增率(%)近三月累計營收存貨銷售比自結稅前EPS自結稅前累計EPS備註(年增率變動50%需說明原因)
2025/20.21172.83324.410.2954.190.43N/A因本期收入及合併子公司收入較去年同期增加,故本月收入較去年同期增加
2025/10.08-46.2-43.660.08-43.660.38N/A-
2024/120.14-9.79-25.681.95-15.470.420.54-
2024/110.1634.29-23.861.81-14.540.490.47-
2024/100.12-43.65-8.721.65-13.510.480.48-
2024/90.2140.772.951.53-13.860.560.38-
2024/80.15-23.94-31.891.32-16.050.560.37-
2024/70.2-9.079.441.17-13.480.620.34-
2024/60.227.161.810.97-17.00.60.35因本公司本月訂單增加及子公司收入增加,故比去年同期收入增加.
2024/50.29.3-18.360.76-27.140.570.37-
2024/40.181.18-25.070.56-29.890.420.5-
2024/30.18267.32-38.20.37-32.080.370.62-
2024/20.05-63.78-74.330.19-24.80.380.6因遇春節連假,交易日減少,故收入比去年同期減少
2024/10.14-29.03149.690.14149.690.540.43因本期增加合併子公司營收,故比去年同期增加
2023/120.19-7.58133.72.31171.360.530.43因本期增加合併子公司營收,故比去年同期增加
2023/110.2160.99329.932.12175.420.540.42因本期增加合併子公司營收,故比去年同期增加
2023/100.13-36.43135.831.91164.960.550.41因本期增加合併子公司營收,故比去年同期增加
2023/90.2-6.86315.881.78167.380.60.31因本期增加合併子公司營收,故比去年同期增加
2023/80.2222.2180.061.57155.50.530.36因本期增加合併子公司營收,故比去年同期增加
2023/70.1834.4320.461.35151.910.560.34因本期增加合併子公司營收,故比去年同期增加
2023/60.13-45.9644.221.17202.540.630.29因本期增加合併子公司營收,故比去年同期增加
2023/50.250.32191.261.04252.340.790.23因本期增加合併子公司營收,故比去年同期增加
2023/40.25-16.54551.570.79277.080.740.24因本期增加合併子公司營收,故比去年同期增加
2023/30.352.55423.330.54216.630.540.39因本期增加合併子公司營收,故比去年用期增加
2023/20.19252.32267.620.25115.490.330.63因本期增加合併子公司營收,故比去年同期增加
2023/10.06-33.57-12.320.06-12.320.191.13-
2022/120.0870.0-12.270.85-17.960.190.21-
2022/110.05-11.683.960.77-18.530.150.26-
2022/100.0612.08-38.70.72-19.70.180.22-
2022/90.05-37.28-4.70.66-17.580.280.18-
2022/80.08-47.43-0.880.62-18.460.320.16-
2022/70.1560.9443.290.54-20.520.330.15-
2022/60.099.12-38.350.39-32.160.220.19-
2022/50.09124.43-20.770.29-29.940.180.22-
2022/40.04-32.97-59.390.21-33.080.150.27因疫情影響,進口藥物交期延宕所致
2022/30.067.16-37.630.17-21.950.170.12-
2022/20.05-15.97-13.790.12-11.00.210.1-
2022/10.06-33.53-8.520.06-8.520.20.1-
2021/120.09101.47-31.411.04-24.690.230.13-
2021/110.05-47.93-56.920.94-23.940.190.16因減少合併子公司故本月營收較同期減少
2021/100.0974.25-27.490.9-20.770.220.14-
2021/90.05-34.76-54.660.81-19.940.240.21因減少合併子公司故本月營收較同期減少
2021/80.08-24.0-42.130.76-15.510.330.15-
2021/70.1-30.76-24.150.68-10.70.360.14-
2021/60.1540.2560.170.57-7.790.350.28本月營收:西藥3,743;試劑8,630;租金收入1,034;售電收入697;其他951
2021/50.1115.03-31.430.42-19.940.290.34-
2021/40.092.94-17.70.31-15.070.250.41-
2021/30.0948.12-18.830.22-13.90.220.18-
2021/20.06-10.84-21.660.13-10.090.270.15-
2021/10.07-50.164.330.074.330.320.13本月營收:西藥2,954;租金收入3,270;售電收入639
2020/120.1426.52-22.191.38117.180.370.13本月營收:西藥2,959;租金收入3,005;售電收入512;顧問收入7,295
2020/110.11-12.36177.791.24171.090.350.14因合併子公司,故本月營收較去年同期增加.本月營收:西藥3,694;租金收入3,088;售電收入592;顧問收入3,510
2020/100.128.95281.881.13170.460.380.13因合併子公司,故本月營收較去年同期增加.本月營收:西藥7,919;租金收入2,742;售電收入806;顧問收入952
2020/90.11-16.73235.031.01161.070.390.13因合併子公司,故本月營收較去年同期增加.本月營收:西藥2,785;租金收入2,864;售電收入878;顧問收入4,871
2020/80.14-0.39247.340.89153.920.370.14因合併子公司,故本月營收較去年同期增加.本月營收:西藥4,472;租金收入2,764;售電收入738;其他-口罩286;顧問收入5,429
2020/70.1446.21241.610.76142.140.390.13因合併子公司,故本月營收較去年同期增加.本月營收:西藥4,931;租金收入1,827;售電收入966;顧問收入6,019
2020/60.09-39.96130.310.62127.640.360.19因合併子公司營收,故本月營收較去年同期增加.本月營收:西藥3,660;租金收入2,021;售電收入885;顧問收入2,833
2020/50.1638.08326.010.53127.170.380.18因合併子公司營收,故本月營收較去年同期增加.本月營收:西藥3,373;租金收入2,352;售電收入517;顧問收入9,414
2020/40.111.52669.190.3789.650.0N/A因合併子公司營收,故本月營收較去年同期大幅增加.本月營收:西藥1,909;租金收入2,049;售電收入818;顧問收入6,562
2020/30.1142.97128.990.2642.210.0N/A因合併子公司營收,故本月營收較去年同期營收增加。本月營收:西藥3,592;租金收入1,758;售電收入756;顧問收入5,062

免責聲明

本網站所有資料僅供參考,如使用者依本資料交易發生交易損失需自行負責,本網站對資料內容錯誤﹑更新延誤不負任何責任。